Is Precision BioSciences, Inc. (DTIL) a Buy, Sell, or Hold?
NASDAQ : DTIL
Precision BioSciences, Inc. — Institutional Ownership
$7.49 USD
$0.07 (0.94%)
- Volume
- 239.58K
- Average Volume
- 410.88K
- Market Capitalization
- $96.08M
- P/E Ratio
- -2.68
- Dividend Yield
- 0.00%
- Price Target
- $19.50
- Year High
- $9.62
- Year Low
- $3.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.82
Institutional Ownership Summary
Institutional Ownership %
%
Investors Holding
change: 0.0 | last:
Increased Positions
change: 0.0 | last:
Reduced Positions
change: 0.0 | last:
New Positions
change: 0.0 | last:
Sold Positions
change: 0.0 | last:
Total Calls
-
Total Puts
-
Put-Call Ratio
change: 0.0 | last:
Total Invested
-
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-07-20 | Lynx1 Capital Management LP | 1.39M | 5.40% |
| 2026-04-15 | Empery Asset Management, LP | 1.97M | 7.63% |
| 2026-02-17 | TANG CAPITAL MANAGEMENT, LLC | - | 0.00% |
| 2026-02-17 | Lynx1 Capital Management LP | 993.91K | 4.10% |
| 2026-02-13 | Bleichroeder LP | 1.9M | 8.21% |
| 2026-02-10 | Octagon Capital Advisors LP | 2.33M | 9.99% |
| 2026-01-27 | Aberdeen Group plc | 2.14M | 8.88% |
| 2026-01-22 | Empery Asset Management, LP | 2.3M | 9.99% |
| 2025-11-14 | LYNX1 CAPITAL MANAGEMENT LP | 1.04M | 8.80% |
| 2025-08-14 | Bleichroeder LP | 1.08M | 9.69% |
| 2025-08-14 | Readout Capital, LP | 1.11M | 9.30% |
| 2025-08-06 | Novartis Pharma AG | 413.58K | 3.70% |
| 2025-08-06 | Aquilo Capital, L.P. | - | 0.00% |
| 2025-05-15 | TANG CAPITAL MANAGEMENT, LLC | 673.33K | 6.40% |
| 2025-04-25 | Highbridge Capital Management, LLC | 406.25K | 3.70% |
| 2025-03-26 | Readout Capital, LP | 920K | 8.80% |
| 2025-03-18 | Weinstein Benjamin | 395.49K | 5.20% |
| 2025-02-14 | Aquilo Capital, L.P. | 521.37K | 6.60% |
| 2025-02-14 | JANUS HENDERSON GROUP PLC | - | 0.00% |
| 2025-02-14 | Lynx1 Capital Management LP | 766.05K | 9.99% |
| 2025-02-12 | Novartis Pharma AG | 413.58K | 5.40% |
| 2024-11-14 | Highbridge Capital Management, LLC | 406.25K | 5.30% |
| 2024-11-14 | Highbridge Capital Management, LLC | 406.25K | 5.30% |
| 2024-03-18 | Aquilo Capital, L.P. | 466.77K | 7.10% |
| 2024-03-18 | Aquilo Capital Management, LLC | 662.66K | 9.90% |
| 2024-03-18 | Marc Schneidman | 662.66K | 9.90% |
| 2024-03-18 | Aquilo Capital, L.P. | 466.77K | 7.10% |
| 2024-03-18 | Aquilo Capital Management, LLC | 662.66K | 9.90% |
| 2024-03-18 | Marc Schneidman | 662.66K | 9.90% |
| 2024-03-14 | Perceptive Advisors LLC | 500K | 7.90% |
| 2024-03-14 | Perceptive Advisors LLC | 500K | 7.90% |
| 2024-03-14 | Joseph Edelman | 500K | 7.90% |
| 2024-03-14 | Perceptive Life Sciences Master Fund, Ltd. | 500K | 7.90% |
| 2024-03-14 | Joseph Edelman | 500K | 7.90% |
| 2024-03-14 | Perceptive Life Sciences Master Fund, Ltd. | 500K | 7.90% |
| 2024-03-11 | EIN #00-0000000 | 511.11K | 8.00% |
| 2024-03-11 | 00-0000000 | 511.11K | 8.00% |
| 2024-02-05 | Tang Capital Management, LLC | 6.4M | 5.20% |
| 2024-02-05 | Tang Capital Management, LLC | 6.4M | 5.20% |
| 2023-02-27 | Dr. Jeffrey R. Jay, M.D. | 8.1M | 7.30% |
| 2023-02-27 | Mr. Ortav Yehudai | 8.1M | 7.30% |
| 2023-02-27 | Mr. Ortav Yehudai | 8.1M | 7.30% |
| 2023-02-27 | Great Point Partners, LLC | 8.1M | 7.30% |
| 2023-02-27 | Dr. Jeffrey R. Jay, M.D. | 8.1M | 7.30% |
| 2023-02-27 | Great Point Partners, LLC | 8.1M | 7.30% |
| 2022-08-31 | Derek Jantz | 4.29M | 3.90% |
| 2022-07-08 | (1) BlackRock, Inc. | 2.38M | 2.40% |
| 2022-07-01 | Dr. Jeffrey R. Jay, M.D. | 5.76M | 5.89% |
| 2022-07-01 | Dr. Jeffrey R. Jay, M.D. | 5.76M | 5.89% |
| 2022-07-01 | Great Point Partners, LLC | 5.76M | 5.89% |
| 2022-07-01 | Mr. Ortav Yehudai | 5.76M | 5.89% |
| 2022-07-01 | Mr. Ortav Yehudai | 5.76M | 5.89% |
| 2022-07-01 | Great Point Partners, LLC | 5.76M | 5.89% |
| 2022-06-27 | Novartis AG | 12.41M | 16.60% |
| 2022-06-27 | Novartis AG | 12.41M | 16.60% |
| 2022-06-27 | Novartis Pharma AG | 12.41M | 16.60% |
| 2022-06-27 | Novartis Pharma AG | 12.41M | 16.60% |
| 2022-02-11 | 95-1411037 | 13.0 | 7.00% |
| 2022-02-10 | Derek Jantz | 4.17M | 6.80% |
| 2022-02-10 | The Vanguard Group - 23-1945930 | 3.24M | 5.34% |
| 2022-02-10 | The Vanguard Group - 23-1945930 | 3.24M | 5.34% |
| 2022-02-03 | (1) BlackRock, Inc. | 4.39M | 7.20% |
| 2021-02-02 | (1) BlackRock, Inc. | 4.02M | 7.70% |
| 2021-01-08 | Eli Lilly and Company | 3.76M | 7.17% |
| 2020-06-08 | Robert Adelman | 3.74M | 7.20% |
| 2020-06-08 | venBio Global Strategic Fund, L.P. | 3.74M | 7.20% |
| 2020-06-08 | venBio Global Strategic GP, Ltd. | 3.74M | 7.20% |
| 2020-06-08 | Corey Goodman | 3.74M | 7.20% |
| 2020-06-08 | venBio Global Strategic GP, L.P. | 3.74M | 7.20% |
| 2020-02-14 | Capital World Investors ** | 4.06M | 7.90% |
| 2020-02-18 | Derek Jantz | 4.2M | 8.20% |
| 2020-02-18 | Derek Jantz | 4.2M | 8.20% |
| 2020-02-14 | Capital World Investors ** | 4.06M | 7.90% |
| 2020-02-07 | (1) BlackRock, Inc. | 2.68M | 5.30% |
| 2019-04-03 | FMR LLC | 3.74M | 7.62% |
| 2019-04-03 | FMR LLC | 3.74M | 7.62% |
DTIL Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $4.16 | 12.83M | $53.36M | $110.82M | $28.81M | -$28.66M |
| 2024-12-31 | $3.81 | 6.83M | $26.03M | $85.9M | $30.04M | -$29.82M |
| 2023-12-31 | $10.95 | 3.84M | $42.06M | $116.68M | $31.27M | -$43.35M |
| 2022-12-31 | $35.70 | 2.93M | $104.6M | $189.58M | $24.96M | -$60.02M |
| 2021-12-31 | $222.00 | 1.96M | $434.29M | $143.66M | $9.11M | $299.74M |
| 2020-12-31 | $250.20 | 1.73M | $433.94M | $89.8M | $10.52M | $354.67M |
| 2019-12-31 | $416.70 | 1.4M | $583.38M | $180.89M | -$ | $402.49M |
| 2018-12-31 | $523.20 | 1.63M | $855.09M | $103.19M | -$ | $751.89M |
| 2017-12-31 | $523.20 | 1.12M | $586.92M | $62.8M | -$ | $524.12M |
| 2016-12-31 | $523.20 | 16.74M | $8.76B | $93.42M | -$ | $8.66B |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7.86 | 25.86M | $203.23M | $86.08M | $1.61M | $118.77M |
| 2026-03-31 | $5.50 | 24.63M | $135.49M | $99.37M | $28.47M | $64.59M |
| 2025-12-31 | $4.16 | 19.05M | $79.25M | $110.82M | $28.81M | -$2.76M |
| 2025-09-30 | $5.52 | 11.82M | $65.24M | $44.87M | $29.13M | $49.49M |
| 2025-06-30 | $4.20 | 11.05M | $46.39M | $62.24M | $29.44M | $13.6M |
| 2025-03-31 | $4.77 | 8.94M | $42.64M | $77.22M | $29.75M | -$4.83M |
| 2024-12-31 | $3.81 | 6.83M | $26.03M | $85.9M | $30.04M | -$29.82M |
| 2024-09-30 | $8.96 | 7.29M | $65.29M | $98.75M | $30.31M | -$3.15M |
| 2024-06-30 | $9.89 | 6.97M | $68.9M | $123.57M | $30.81M | -$23.86M |
| 2024-03-31 | $15.37 | 5.06M | $77.79M | $137.77M | $31.05M | -$28.93M |
| 2023-12-31 | $10.95 | 4.45M | $48.74M | $116.68M | $31.27M | -$36.67M |
| 2023-09-30 | $10.23 | 3.84M | $39.27M | $122.23M | $23.86M | -$59.1M |